Portfolio News

 

   
June 24, 2016
Carbylan Therapeutics, Inc. and KalVista Pharmaceuticals Ltd. Enter into Share Purchase Agreement
Carbylan Therapeutics, Inc. and KalVista Pharmaceuticals Ltd. Enter into Share Purchase Agreement   --Transaction forms combined NASDAQ-listed biopharmaceutical company, focused on the discovery, development and commercialization of plasma kallikrein inhibitors for the treatment of hereditary angioedema (HAE) and diabetic macular edema (DME)   --KalVista to become a wholly owned subsidiary of Carbylan, and KalVista shareholders to become majority owners of Carbylan upon the closing ...

Read more

Team - Kate Bingham
September 3, 2015
Allergan to Acquire Glaucoma Treatment Company AqueSys to Add Minimally Invasive Implantable Shunt to Eye Care Offering
DUBLIN and ALISO VIEJO, Calif., Sept. 3, 2015 /PRNewswire/ -- Allergan plc AGN, -0.45% a leading global pharmaceutical company, and AqueSys, Inc. a private clinical stage medical device company focused on developing ocular implants that reduce intraocular pressure (IOP) associated with glaucoma, today announced that they have entered into an agreement under which Allergan will acquire AqueSys in an all-cash transaction.

Read more

July 31, 2015
FDA Approval of ReShape™ Dual Balloon Marks Significant Step for the Weight Loss Program in Helping at Risk Group of Patients
Obesity is on the rise and is a worldwide epidemic. A recent Lancet study noted that the chance of an obese person becoming normal weight is less than .5%. Currently in the United States, the obese population outnumbers the overweight population. Bariatric surgery helps patients with severe obesity in terms of weight loss, reduction in severity and number of comorbid conditions. This week the U.S.

Read more

January 2015
Entellus Medical - IPO
SV Life Sciences Advisers notes that Entellus Medical successfully listed on NASDAQ on 29 January 2015 The business wire press release is below Nasdaq Welcomes Entellus Medical, Inc. (Nasdaq: ENTL) to The Nasdaq Stock Market NEW YORK, Jan. 29, 2015 (GLOBE NEWSWIRE) -- Nasdaq (Nasdaq:NDAQ) announced that trading of Entellus Medical, Inc. (Nasdaq:ENTL), a medical technology company, commenced on The Nasdaq Stock Market on January 29, 2015.

Read more

Team - Paul LaViolette, David Milne
January 2015
Sale of Convergence Pharmaceuticals
SV Life Sciences Fund V notes that Biogen Idec (NASDAQ: BIIB) acquired Convergence from its owners, SV Life Sciences and others, for a possible total of $675m - $200m upfront and $475m of milestone based payments.  Convergence Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of treatments for chronic pain.  Biogen Idec Press release   ...

Read more

Team - Kate Bingham
December 2014
Oncoethix Exit
SV Life Sciences Fund V notes that Merck acquired Oncoethix from its owners, SV Life Sciences and others, for an upfront payment of $110m. Additional milestone payments of up to $265m are contingent upon clinical and regulatory events being achieved. Oncoethix is a clinical stage biotechnology company developing innovative cancer drugs. . Merck Press Release ...

Read more

Team - Kate Bingham, Michael Carter
May 2014
Urgent Team Holdings
SV Life Sciences Fund V invested in Urgent Team Holdings (UTH) as part of a $10.2m series B financing round. UTH own and operate a regional network of urgent care facilities in the Southern United States.   ...

Read more

Team - Tom Flynn, Eugene Hill
May 2014
Avitide
SV Life Sciences Fund V invested in Avitide as part of a $3.4m Series B financing round. Avitide is a biopharmaceutical company dedicated to the discovery and development of affinity purification products that will improve the fundamental timeframes and economics of commercial bioprocessing.   ...

Read more

Team - Michael Ross
January 2014
Thesan Pharmaceticals
SV Life Sciences V invested in Thesan Pharmaceuticals, a dermatology company focused on therapeutics for the treatment of atopic dermatitis and acne, as part of a $49m series B financing round.  ...

Read more

Team - Michael Ross
January 2014
Maestro Healthcare Technology Investment
SV Life Sciences Advisers notes that SV Life Science Fund V invested in Maestro Healthcare, Technology-enabled healthcare service company that sells defined contribution plans to employers via private exchange as part of a seed loan financing round. ...

Read more

Team - Tom Flynn, Eugene Hill
January 2014
AqueSys Investment
SV Life Sciences notes that SV Life Sciences Fund V invested in AqueSys, maker of proprietary implants for glaucoma-related vision loss, the world’s No. 2 cause of blindness as part of a $42m series D financing round.  ...

Read more

Team - David Guyer, David Milne
December 2013
CSA Medical
SV Life Sciences Fund V invested in CSA Medical, the leading developer of novel Spray Cryotherapy devices that freeze and destroy unwanted tissue inside the body, as part of a $16m financing round. ...

Read more

Team - Paul LaViolette, David Milne
December 2013
Rempex Pharmacuticals Exit
SV Life Sciences notes that on 04 December 2013 – The Medicines Company (NASDAQ: MDCO) entered in to a definitive agreement to purchase Rempex Pharmaceuticals for an upfront payment price of $140m and has agreed to pay Rempex equity holders milestone payments subsequent to closing. ...

Read more

Team - Michael Ross
November 2013
Sutro Biopharma
SV Life Science Fund V invested in Sutro Biopharma, an on-going development of low cost, high quality rapidly developed protein pharmaceuticals and innovative vaccines, as part of a $26m series D financing round.  ...

Read more

Team - Michael Ross

⇧ Back to top